BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ubrogepant (Ubrelvy) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ubrogepant (Ubrelvy)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05125302-10391@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05125302)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study to Ass
 ess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the
  Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05125302
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417775-10391@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT06417775)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study of Ora
 l Ubrogepant to Assess Adverse Events and Change in Disease Activity in Ad
 ult Participants With Menstrual Migraine\nEstimated primary completion: No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ubrogepa
 nt-ubrelvy#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06417775
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05127954-10391@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05127954)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Long-term Ex
 tension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets
  for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
 \nEstimated primary completion: January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05127954
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
